Join
Live feed
·
INSIDERFilingvia Quantisnow
Relay Therapeutics Inc. logo

Chief Financial Officer Catinazzo Thomas sold $349,734 worth of shares (17,717 units at $19.74) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 140,568 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RLAY· Relay Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RLAY (Relay Therapeutics Inc.) and more on Quantisnow.